Duloxetine Capsule, Delayed Release
Product Images NDC 71610-403

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71610-403). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 60 mg (71610 0403 60)

Label for Duloxetine DR 60 mg delayed-release capsules, 90 count, manufactured by Ajanta Pharma Limited and distributed by Aphena Pharma Solutions - Tennessee, LLC. The label includes storage instructions, dosage form, strength, quantity, and regulatory information such as the NDC number 71610-0403-60.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure01 (Duloxetine Fig01)

A Kaplan-Meier curve chart depicting the proportion of patients with relapse over time in days from randomization. The graph compares treatment with Duloxetine and placebo, showing relapse rates on the y-axis and days on the x-axis up to 200 days. Duloxetine is represented with a solid line, and placebo is shown with a dashed line.*

FDA Label Image

Figure2 (Duloxetine Fig02)

A Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over time (days) from randomization between Duloxetine and placebo treatments. The y-axis indicates the proportion of patients with relapse, and the x-axis represents time in days, up to 300 days. The chart shows two curves: one for Duloxetine and one for placebo.*

FDA Label Image

Figure03 (Duloxetine Fig03)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo across various levels of pain improvement.*

FDA Label Image

Figure04 (Duloxetine Fig04)

A line graph showing the percentage of patients improved against percent improvement in pain from baseline. It compares Duloxetine 60 mg administered twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo groups, illustrating patient response rates at various pain improvement levels.*

FDA Label Image

Figure07 (Duloxetine Fig07)

This line graph compares the percentage of patients improved in pain from baseline between a placebo group and patients treated with Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Data indicate higher patient improvement percentages with Duloxetine across increasing pain improvement thresholds.*

FDA Label Image

Figure08 (Duloxetine Fig08)

A line graph comparing the percentage of patients improved at various percent improvement thresholds in pain from baseline (BOCF). The graph shows two data sets: placebo (dotted line with x markers) and duloxetine 60 mg once daily (solid line with diamond markers). The Y-axis represents the percentage of patients improved, ranging from 0 to 100%, and the X-axis shows percent improvement in pain from baseline in increments of 10% from >0 to 100%. Vertical dashed lines are present at 30% and 50% improvement.*

FDA Label Image

Figure09 (Duloxetine Fig09)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between Placebo and Duloxetine 60/120 mg once daily. The X-axis represents percent improvement in pain from baseline, ranging from over 0 to 100%. The Y-axis shows the percentage of patients improved, from 0 to 100%. The graph displays two lines: one with diamond markers for Duloxetine and one with X markers for Placebo, showing higher patient improvement percentages for Duloxetine across most pain improvement percentages.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride shown as a molecular diagram including thiophene and naphthalene rings, indicating the arrangement of atoms and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.